Logo image of KRTX

KARUNA THERAPEUTICS INC (KRTX) Stock News

NASDAQ:KRTX - Nasdaq - US48576A1007 - Common Stock - Currency: USD

329.83  +0.09 (+0.03%)

After market: 329.83 0 (0%)

KRTX Latest News, Press Relases and Analysis

News Image
a year ago - Benzinga

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect

Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.

Mentions: XLK XLV BSX DHR ...

News Image
a year ago - Seeking Alpha

Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb

Karuna Therapeutics (KRTX) experienced a temporary stock decline of 7.6%, but has since recovered to a 2% loss.

Mentions: BMY MS

News Image
a year ago - Seeking Alpha

Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29 (NASDAQ:KRTX)

Karuna Therapeutics reports Q4 financial results, with a GAAP EPS of -$3.01, missing expectations by $0.29.

News Image
a year ago - InvestorPlace

Mental Health Mavericks: 3 Stocks Changing the Game

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Mentions: PSIL BMY ACHC CMPS

News Image
a year ago - Seeking Alpha

Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)

Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.

Mentions: BMY MRTX RYZB

News Image
a year ago - Seeking Alpha

Karuna’s KarXT is Evaluate's most anticipated drug for 2024

Evaluate Vantage ranks Karuna Therapeutics'(KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.

Mentions: BMY LLY BIIB

News Image
a year ago - Seeking Alpha

Karuna’s KarXT tops Evaluate’s most anticipated drug list (NYSE:BMY)

Evaluate Vantage ranks Karuna Therapeutics' (KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.

Mentions: BMY LLY BIIB

News Image
a year ago - Seeking Alpha

Bristol-Myers almost lost Karuna buyout to third party (NYSE:BMY)

Bristol Myers Squibb (BMY) successfully fought to acquire Karuna Therapeutics (KRTX) in a $14B deal, outmaneuvering another large pharma bidder. Read more here.

Mentions: BMY

News Image
a year ago - Seeking Alpha

Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)

Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping

Mentions: BMY JPM MRTX RYZB

News Image
a year ago - Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Mentions: LLY ARWR XBI BMY ...

News Image
a year ago - Seeking Alpha

Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)

Bank of America downgrades Bristol-Myers Squibb (BMY) to Neutral due to concerns over upcoming patent expiries. Read more here.

Mentions: BMY BAC MRTX RYZB

News Image
a year ago - Seeking Alpha

What's in store for biotech M&A and IPOs in 2024? (NYSE:BMY)

Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.

Mentions: BMY ABBV PFE IMGN ...

News Image
a year ago - Investor's Business Daily

Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review

The major indexes boast big annual gains with the Dow at record highs.

Mentions: TSLA BMY LI NIO ...